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n INTRODUCTION
S
taphylococcus aureus is one of the main
causes of infective endocarditis (IE) in in-
dustrialised countries, and S. aureus endo-
carditis is often associated with several clinical
manifestations and complications in the form of
fever with metastatic infection, heart failure
and central nervous system involvement [1-3].
An increasing proportion of S. aureus endo-
carditis cases are methicillin-resistant S. aureus
(MRSA), and methicillin-resistance is on the
rise in intravenous drug users who generally
show less favourable outcomes after treatment,
as well as more frequent and potentially life-
threatening complications [3, 4].
Large vegetation carries a poor prognosis and
high mortality risk, especially if associated with
MRSA infection [5]. Early diagnosis and imme-
diate commencement of effective antibiotic ther-
apy is imperative in saving lives. Although op-
timal medical management consists of antimi-
crobial medications, extensive and complicated
cases of IE are currently mainly treated with
parenteral antibiotics and cardiac surgery [6, 7].
To contribute to better management of severe
complicated IE, in terms of determining treat-
ment strategies, we describe a complex case of
recurrent MRSA mitral valve endocarditis.
n CASE PRESENTATION
In June 2010, a 35-year-old male HCV-positive
intravenous drug user of Italian origin came to
the Emergency Department of the Paolo Giac-











mental confusion and numbness of the limbs
that he had been experiencing for five days. A
review of his medical history revealed previous
MSSA endocarditis and mitral valve repair
surgery. A human immunodeficiency virus test
performer on admission was negative. 
Clinical examination revealed his blood pres-
sure to be 100/80 mmHg and his pulse was 110
beats/min and regular. His electrocardiogram
was unremarkable. Auscultation revealed a
harsh 3/6 holosystolic murmur, best heard at
the cardiac apex, radiating to the sternum. Ini-
tial laboratory tests showed a WBC count of
7.54×103/L (85.4% neutrophils, 9% lympho-
cytes, and 4.9% monocytes), Hb 12.8 g/L, ALT
53 U/L (normal range 5-45 U/L), AST 58 U/L
(normal range 5-45 U/L), GGT 120 U/L (nor-
mal range 4-50 U/L), ALP 224 U/L (normal
range 42-128 U/L) and serum C-reactive pro-
tein levels (CRP) of 15 mg/dl (normal range
0.08-1.5 mg/dl). Coagulation parameters, renal
function and urine and OGTT were all normal. 
The stroke team was alerted and the patient
was given standard emergency room assess-
ment and treatment. A CT image of the brain
showed frontal and insular sub-arachnoid
haemorrhage. His angiogram was normal. A
transthoracic echocardiogram revealed a large
vegetation 1 cm x 1 cm adhering to the mitral
leaflets and protruding into the left atrium
(Figure 1). 
S. aureus DNA was detected by LightCycler
SeptiFast and empiric intravenous antimicro-
bial treatment with vancomycin (35 mg/kg per
day by continuous infusion) and gentamicin (5
mg/kg/day) was started [8]. 
12 hours after admission, the patient showed
cardiac conduction abnormalities progressing
to Mobitz type I second-degree atrioventricular
block (ECG findings) and he was moved to the
Cardiac Intensive Care Unit (CICU). The pa-
tient’s condition steadily worsened and pe-
techial exanthema appeared. 
Blood culture grew MRSA. The antimicrobial
susceptibility test was carried out using previ-
ously described methods, in accordance with
Clinical and Laboratory Standards Institute
guidelines [9]. The isolate was susceptible to co-
trimoxazole (TMP/SMX), linezolid, tigecycline
and daptomycin and resistant to rifampin,
tetracycline, ciprofloxacin, piperacillin-tazobac-
tam, aminoglycosides and macrolides. Van-
comycin minimum inhibitory concentration
(MIC) was 2 µg/ml. SCCmec type was deter-
mined using previously described primers and
conditions (10). The isolate was attributed with
SCCmec IVa. 
We decided to shift antibiotic treatment to 8
mg/kg/day of daptomycin every 24 hours and
15 mg/kg/day of TMP/SMX administered in-
travenously in three equal doses. By the 25th
day, the vegetation had reduced from 1 cm to
0.6 cm and the patient’s clinical conditions had
improved. 
Considering the size of the vegetation, its hyper
mobility and the associated systemic embolic
event, surgical re-repair was judged to be es-
sential and proposed to the patient. Neverthe-
less, despite our concerns for his health, he did
not consent to cardiac surgery. 
After six weeks of combination intravenous an-
tibiotic treatment with daptomycin plus
TMP/SMX, the patient was discharged on a
high dose of TMP/SMX (320 mg/1,600 mg
twice daily) for six weeks and referred for out-
patient follow-up. High-dose TMP/SMX treat-
ment was well tolerated in our patient through-
out the treatment course. At the end of the pre-
scribed course of treatment, the patient came
back for a check-up: trans-oesophageal echocar-
diography showed that the vegetation had dis-
appeared and edges had thickened.
n DISCUSSION
Our results further contribute to showing that
it may be difficult to follow guidelines on start-
ing antimicrobial therapy because different
MRSA isolates have varying antimicrobial sus-
ceptibility patterns in different geographic ar-
eas [10-12]. 
Figure 1 - Image along the parasternal axis. The lar-
ge vegetation, about 1x1 cm, can be seen in the an-




Because severe infections such as cerebral em-
bolism in the course of infective endocarditis
require quick and effective treatment, we re-
sorted to SeptiFast to identify the isolate rapid-
ly and adopt more accurate empiric treatment.
In our patient’s case, we believe the Septifast
procedure was in support of microbiological di-
agnosis. Accurate identification of blood isolate
and its antimicrobial susceptibility was central
to the optimal management of our case report. 
Our initial therapeutic approach was to sup-
pose that the S. aureus strain was methicillin-re-
sistant as the patient had a history of surgery,
previous anti-staphylococcal treatment and
chronic liver disease. Moreover, we took into
account our recent epidemiology and the circu-
lation patterns of MRSA clones, as well as the
literature which frequently shows different an-
timicrobial susceptibility patterns of these
strains [12]. Our patient‘s history and the phe-
notypic and molecular characteristics of the
MRSA isolate would suggest a community
strain, though susceptibility to non--lactams
and SCCmecIV have proved to be also shared
by some epidemic clones of HA-MRSA, such as
EMRSA-15, that are widely circulating in our
geographic area [11].
For several years, glycopeptides have been con-
sidered the antimicrobials of choice for serious
MRSA and methicillin-resistant coagulase-neg-
ative staphylococci (MR-CoNS) infections [13-
15]. However, a literature search found no pub-
lished studies of the effects of vancomycin ex-
posure on outcomes and hospital costs in pa-
tients with complicated bacteraemia or IE due
to MRSA. 
In our patient’s case, we initially considered
continuous vancomycin infusion because this
drug remains the first line antimicrobial for
community-acquired and nosocomial infec-
tions due to MRSA, and because data support
theoretical arguments that higher and more
sustained serum levels of vancomycin, ob-
tained by continuous infusion, may enhance
clinical efficacy. 
In our patient’s case, the S. aureus isolate
showed a vancomycin MIC of 2 mg/mL which
was considered to be perhaps less effective
against serious methicillin resistance, or a
“bridge too far” in that the doses required car-
ried a significant risk of toxicity [14]. Guidelines
therefore recommend therapy with alternative
antimicrobials [16]. 
Close et al. have recently shown that TMP-SMX
15 mg/kg/day is an option in the management
of GISA infection [17]. Although some anecdo-
tal reports suggest successful therapy with
TMP-SMX for a variety of S. aureus infections,
clonal outbreaks of MRSA resistant to TMP-
SMX have been described [17-19]. The role of
folate antagonist for treatment of MRSA infec-
tion has been recently suggested because TMP-
SMX is bactericidal and well tolerated; it is an-
timicrobial with high tissue penetration that re-
duced cytokine production after SA toxin expo-
sure [20]. It is also inexpensive. [19]. 
On the other hand, antimicrobial association
against S. aureus may be chosen to increase bac-
tericidal activity in cases of severe infection, es-
pecially during complicated IE. Over the
decades, in vitro and in vivo studies of bacterici-
dal interactions of antimicrobial molecules
against S. aureus have yielded conflicting re-
sults [21]. 
Daptomycin is a well-known alternative treat-
ment option for infective endocarditis; studies
on the synergistic effects of daptomycin in com-
bination with other antibiotics including gen-
tamicin, rifampin, beta-lactams, TMP-SMX or
clarithromycin present a new therapeutic ap-
proach [22-24]. In our case report, the antimi-
crobial susceptibility of the strain led us to com-
bine new molecules like daptomycin with old-
er, low cost antibiotics such as TMP/SMX.
Moreover, the combination of TMP/SMX and
daptomycin is justified by how they act syner-
gistically to provide rapid bactericidal activity
and reduce daptomycin resistance. 
In conclusion, our case report could expand the
clinician’s understanding of contemporary
drug therapy and represent a challenging case
in currently-debated filed of research. Future
studies are needed to evaluate available clinical
and pharmacokinetic/pharmacodynamic (PK/
PD) evidence regarding TMP/SMX, particular-
ly in association with other antibacterials such
as daptomycin. 




Large cardiac vegetation carries a poor prognosis
and high mortality risk, especially if associated
with methicillin-resistant Staphylococcus aureus
(MRSA) infection. We share our experience of a
rare and complicated large cardiac vegetation
which had a favourable outcome with combina-
tion antibiotic treatment alone. A 35-year-old HIV-
negative, HCV-positive male patient with a previ-
ous history of methicillin-susceptible S. aureus en-
docarditis showed MRSA mitral valve endocardi-
tis with large vegetation, complicated by embolic
stroke. The strain was soon identified by PCR but
only after culture did the patient receive effica-
cious antibiotics. A combination of daptomycin
plus trimethoprim/sulfamethoxazole (TMP/SMX)
was administered for six weeks, followed by a
high dosage of TMP/SMX for a further six weeks.
Effectiveness of the treatment was demonstrated
by the patient’s clinical improvement and instru-
mental evidence of cardiac mitral vegetation clear-
ance. Innovative antibiotic strategies in patient
management are needed to fight Staphylococcus au-
reus endocarditis because strains show varying an-
timicrobial susceptibility patterns in different geo-
graphic areas. Timely initiation of targeted antimi-
crobial therapy remains a crucial step to reduce
morbidity and mortality but culture is crucial for
appropriate fine-tuning of antibiotic therapy.
SUMMARY
La presenza di un’estesa vegetazione cardiaca comporta
una prognosi sfavorevole e un alto rischio di mortalità,
soprattutto se questa è associata a un’infezione da
Staphylococcus aureus meticillino resistente (MR-
SA). Qui di seguito gli autori riportano un caso di en-
docardite su valvola mitralica da MRSA caratterizzata
da un’estesa e mobile vegetazione (>1,2cm) e complica-
ta da stroke embolico, in un paziente di 35 anni HIV-ne-
gativo, HCV-positivo con pregressa storia clinica di en-
docardite da S. aureus meticillino-sensibile (MSSA) ed
intervento di valve repair. Lo S. aureus è stato ini-
zialmente identificato con metodica di LightCycler Sep-
tiFast, ma solo dopo esame colturale il paziente ha rice-
vuto una terapia antibiotica efficace. La combinazione di
daptomicina e trimetoprim-sulfametossazolo (TMP/
SMX) per via e.v. è stata somministrata per sei setti-
mane e poi continuata nelle successive sei settimane con
solo TMP/SMX ad alte dosi per os. L’efficacia del trat-
tamento è stata dimostrata dal miglioramento delle con-
dizioni cliniche del paziente e dalla clearance della ve-
getazione. Trattamenti antibiotici innovativi nella ge-
stione del paziente sono necessari per contrastare le en-
docarditi da S. aureus, e in particolare da MRSA, poi-
ché i ceppi hanno mostrato variegati profili di sensibilità
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